Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2016

01-01-2016 | Original Article

Prognostic significance of human tissue kallikrein-related peptidases 11 and 15 in gastric cancer

Authors: David L. Kolin, Keiyan Sy, Fabio Rotondo, Mena N. Bassily, Kalman Kovacs, Christine Brezden-Masley, Catherine J. Streutker, George M. Yousef

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

Human tissue kallikrein-related peptidases (KLK) are a group of 15 serine proteases which have been investigated as potential cancer biomarkers. This study determined the prognostic significance of KLK 11 and 15 expression levels in gastric carcinoma specimens. Expression of KLK11 and KLK15 was assessed by immunohistochemistry staining on a tissue microarray constructed from 113 gastrectomy specimens from patients with gastric carcinoma. To minimize inter-observer variability, expression levels were quantified using an automated algorithm. Epithelial and stromal staining were assessed separately. Both KLK11 and KLK15 were expressed in gastric carcinoma. There was no significant correlation between either KLK11 or KLK15 expression and the presence of lymph node metastases or Lauren classification (intestinal vs. diffuse). Higher levels of KLK11 expression in gastric carcinoma were associated with significantly worse overall survival (p = 0.008), and a multivariate analysis showed that it had prognostic value independent of tumor stage and differentiation (p = 0.004). Variations in KLK15 expression were not significantly associated with prognosis. KLK11 shows promise as a potential independent prognostic marker for gastric carcinoma.
Literature
1.
Ferlay J, Soerjomataram II, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136:E359–86.CrossRefPubMed
2.
3.
Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2014. Toronto; 2014.
4.
Shah MA, Ajani JA. Gastric cancer—an enigmatic and heterogeneous disease. JAMA. 2010;303:1753–4.CrossRefPubMed
5.
Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–9.CrossRefPubMed
6.
Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev. 2001;22:184–204.PubMed
7.
Shaw JLV, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007;53:1423–32.CrossRefPubMed
8.
Yousef GM, Scorilas A, Jung K, Ashworth LK, Diamandis EP. Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J Biol Chem. 2001;276:53–61.CrossRefPubMed
9.
Borgoño CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer. 2004;4:876–90.CrossRefPubMed
10.
Yousef GM, Obiezu CV, Luo L-Y, Magklara A, Borgoño CA, Kishi T, et al. Human tissue kallikreins: from gene structure to function and clinical applications. Adv Clin Chem. 2005;39:11–79.CrossRefPubMed
11.
Kontos CK, Scorilas A. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clin Chem Lab Med. 2012;50:1877–91.CrossRefPubMed
12.
Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem. 2008;54:1600–7.CrossRefPubMed
13.
Kontos CK, Mavridis K, Talieri M, Scorilas A. Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: mechanistic and clinical aspects. Thromb Haemost. 2013;109:450–7.CrossRef
14.
Patsis C, Yiotakis I, Scorilas A. Diagnostic and prognostic significance of human kallikrein 11 (KLK11) mRNA expression levels in patients with laryngeal cancer. Clin Biochem. 2012;45:623–30.CrossRefPubMed
15.
Yousef GM, Scorilas A, Katsaros D, Fracchioli S, Iskander L, Borgono C, et al. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol. 2003;21:3119–26.CrossRefPubMed
16.
Yousef GM, Scorilas A, Magklara A, Memari N, Ponzone R, Sismondi P, et al. The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. Br J Cancer. 2002;87:1294–300.CrossRefPubMedPubMedCentral
17.
Nakamura T, Stephan C, Scorilas A, Yousef GM, Jung K, Diamandis EP. Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. Urology. 2003;61:1042–6.CrossRefPubMed
18.
Bi X, He H, Ye Y, Dai Q, Han Z, Liang Y, et al. Association of TMPRSS2 and KLK11 gene expression levels with clinical progression of human prostate cancer. Med Oncol. 2010;27:145–51.CrossRefPubMed
19.
Stavropoulou P, Gregorakis AK, Plebani M, Scorilas A. Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clin Chim Acta. 2005;357:190–5.CrossRefPubMed
20.
Rabien A, Fritzsche FR, Jung M, Tölle A, Diamandis EP, Miller K, et al. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. Int J Cancer. 2010;127:2386–94.CrossRefPubMed
21.
Mavridis K, Stravodimos K, Scorilas A. Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression. Prostate. 2013;73:1191–201.CrossRefPubMed
22.
Wen Y-G, Wang Q, Zhou C-Z, Yan D-W, Qiu G-Q, Yang C, et al. Identification and validation of Kallikrein-ralated peptidase 11 as a novel prognostic marker of gastric cancer based on immunohistochemistry. J Surg Oncol. 2011;104:516–24.CrossRefPubMed
23.
Lei K-F, Liu B-Y, Zhang X-Q, Jin X-L, Guo Y, Ye M, et al. Development of a survival prediction model for gastric cancer using serine proteases and their inhibitors. Exp Ther Med. 2012;3:109–16.CrossRefPubMed
24.
Kolin DL, Sy K, Rotondo F, Bassily MN, Kovacs K, Brezden-Masley C, et al. Prognostic significance of human tissue kallikrein-related peptidases 6 and 10 in gastric cancer. Biol Chem. 2014;395:1087–93.CrossRefPubMed
25.
Liu XL, Wazer DE, Watanabe K, Band V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res. 1996;56:3371–9.PubMed
26.
Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001;23:291–9.PubMed
27.
Linder N, Konsti J, Turkki R, Rahtu E, Lundin M, Nordling S, et al. Identification of tumor epithelium and stroma in tissue microarrays using texture analysis. Diagn Pathol. 2012;7:22.CrossRefPubMedPubMedCentral
28.
Fadem B. High-yield behavioral science (high-yield series). Hagerstwon: Lippincott Williams & Wilkins; 2008.
29.
30.
Freedman DA. Statistical models: theory and practice. Cambridge: Cambridge University Press; 2005.CrossRef
31.
Feng B, Xu W-B, Zheng M-H, Ma J-J, Cai Q, Zhang Y, et al. Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer. J Gastroenterol Hepatol. 2006;21:1596–603.CrossRefPubMed
32.
Liu X, Xiong H, Li J, He Y, Yuan X. Correlation of hK6 expression with tumor recurrence and prognosis in advanced gastric cancer. Diagn Pathol. 2013;8:62.PubMedPubMedCentral
33.
Kim JJ, Kim J-T, Yoon HR, Kang MA, Kim JH, Lee Y-H, et al. Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer. Tumour Biol. 2012;33:731–8.CrossRefPubMed
34.
Scorilas A, Mavridis K. Kallikrein-related peptidases (KLKs) as novel potential biomarkers in gastric cancer: an open yet challenging road lies ahead. J Surg Oncol. 2012;105:223–4.CrossRefPubMed
35.
Sawant S, Snyman C, Bhoola K. Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms. Int Immunopharmacol. 2001;1:2063–80.CrossRefPubMed
36.
Yousef GM, Borgoño CA, White NM, Robb J-D, Michael IP, Oikonomopoulou K, et al. In silico analysis of the human kallikrein gene 6. Tumour Biol. 2004;25:282–9.CrossRefPubMed
37.
Nagahara H, Mimori K, Utsunomiya T, Barnard GF, Ohira M, Hirakawa K, et al. Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res. 2005;11:6800–6.CrossRefPubMed
38.
Zhao E-H, Shen Z-Y, Liu H, Jin X, Cao H. Clinical significance of human kallikrein 12 gene expression in gastric cancer. World J Gastroenterol. 2012;18:6597–604.CrossRefPubMedPubMedCentral
39.
Konstantoudakis G, Florou D, Mavridis K, Papadopoulos IN, Scorilas A. Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. Clin Biochem. 2010;43:1205–11.CrossRefPubMed
40.
Huang W, Zhong J, Wu L-Y, Yu L-F, Tian X-L, Zhang Y-F, et al. Downregulation and CpG island hypermethylation of NES1/hK10 gene in the pathogenesis of human gastric cancer. Cancer Lett. 2007;251:78–85.CrossRefPubMed
41.
Unal D, Tasdemir A, Oguz A, Eroglu C, Cihan YB, Turak EE, et al. Is human kallikrein-11 in gastric cancer treated with surgery and adjuvant chemoradiotherapy associated with survival? Pathol Res Pract. 2013;209:779–83.CrossRefPubMed
42.
Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One. 2012;7:e37379.CrossRefPubMedPubMedCentral
43.
Sano A, Sangai T, Maeda H, Nakamura M, Hasebe T, Ochiai A. Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3. Int J Oncol. 2007;30:1493–8.PubMed
44.
Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17:3077–9.CrossRefPubMed
Metadata
Title
Prognostic significance of human tissue kallikrein-related peptidases 11 and 15 in gastric cancer
Authors
David L. Kolin
Keiyan Sy
Fabio Rotondo
Mena N. Bassily
Kalman Kovacs
Christine Brezden-Masley
Catherine J. Streutker
George M. Yousef
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3802-7

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue

Original Article

Bioinformatic analyses revealed underlying biological functions correlated with oxaliplatin responsiveness

Original Article

RETRACTED ARTICLE: The critical role of HMGA2 in regulation of EMT in epithelial ovarian carcinomas

Review

IL-22: a promising candidate to inhibit viral-induced liver disease progression and hepatocellular carcinoma

Original Article

The involvement of survivin in insulin-like growth factor 1-induced epithelial-mesenchymal transition in gastric cancer

Original Article

RND1 is up-regulated in esophageal squamous cell carcinoma and promotes the growth and migration of cancer cells

Original Article

Synergistic action of 5Z-7-oxozeaenol and bortezomib in inducing apoptosis of Burkitt lymphoma cell line Daudi
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits